Clinical trials: Non-communicable Diseases
Anterior Uveitis
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- NCT01505088
- Testing
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution
- Where
- 39 sites in United States
- Volunteers
- 193 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Chronic Hepatitis C Infection
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (what the body does to the medication) and antiviral activity of JNJ-47910382 when administered in different dosing regimens in Caucasian…
- Trial name
- NCT01651767
- Testing
- JNJ-47910382
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Janssen R&D Ireland
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
The study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- PEACHTREE (NCT02595398)
- Testing
- 4mg CLS-TA Suprachoriodal Injection
- Where
- 64 sites in United States, India and 1 more
- Volunteers
- 160 people
- Sponsor
- Clearside Biomedical, Inc.
HIV Infection, Hepatitis C
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
- Trial name
- NCT00141284
- Testing
- nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Pfizer
HIV Infections
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on…
- Trial name
- NCT07650916
- Testing
- CAB ULA, RPV ULA, CAB LA
- Where
- 108 sites in United States, Argentina and 8 more
- Volunteers
- 564 people
- Sponsor
- ViiV Healthcare
Infection
LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection
The primary objective is: to assess the microbiological success of the combination of levofloxacin and rifampicin, administered for 32 to 37 days, as oral replacement therapy of an empirical antibiotic therapy of a maximum of 5…
- Trial name
- NCT00906048
- Testing
- Levofloxacin (HR355) and Rifampicin Therapy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Sanofi
Uveitis
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- Trial name
- Visual II (NCT01124838)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 261 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Cough
Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough
Primary objective: To assess the efficacy of Levopront® in comparison with Libexin® based on daytime cough resolution rate by Day 8.
- Trial name
- LDP0114 (NCT03837938)
- Testing
- Levopront® syrup 30 mg/5 ml, Libexin®
- Where
- 8 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Dompé Farmaceutici S.p.A
Acquired Immunodeficiency Syndrome, Healthy Volunteers
Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
This study is intended to evaluate: 1. Any changes in the gut microbiome from baseline compared to end of study in both healthy (HIV-negative) subjects and HIV+ patients with or without chronic diarrhea, following one month of…
- Conditions
- Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea
- Trial name
- NCT04192487
- Testing
- Crofelemer delayed-release tablets 125mg
- Where
- 3 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Napo Pharmaceuticals, Inc.
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing…
- Trial name
- NCT01798576
- Testing
- Pegylated Interferon alfa-2a, Ribavirin
- Where
- Romania
- Volunteers
- 282 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Chickenpox
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
- Trial name
- NCT00002358
- Testing
- Sorivudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Hepatitis B, Hepatitis A
Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults
This protocol posting describes the booster phase of the study. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00289731).
- Trial name
- NCT00603252
- Testing
- Twinrix, Engerix-B, Havrix
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-infectious Uveitis
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis
The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.
- Trial name
- BSX-003 (NCT00646425)
- Testing
- Basiliximab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cerimon Pharmaceuticals
Hepatitis C
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV…
- Trial name
- NCT00420784
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 465 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV Infection
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
The purpose of this study is to measure viral tropism over time in subjects with X4-tropic or non-phenotypeable virus while receiving standard of care therapy. This is an observational study.
- Trial name
- NCT00321438
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
HIV-1-infection
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA <50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).
- Trial name
- BIC-STaR (NCT03580668)
- Testing
- B/F/TAF
- Where
- 6 sites in Canada
- Volunteers
- 201 people
- Sponsor
- Gilead Sciences
Schistosoma Hematobium Infection, Schistosomiasis Mansoni
Safety and Efficacy of Mirazid for Schistosomiasis Treatment
Clinical Trial Phase:Phase III Primary Objectives: Compare Mirazid and Praziquantel cure rates for both Schistosoma species. Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both Schistosoma…
- Trial name
- PHAR0211 (NCT01529710)
- Testing
- Myrrh
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Pharco Pharmaceuticals
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
This prospective, multi-center, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) in participants with previously untreated chronic hepatitis C, genotype 2, 3, 1…
- Trial name
- PEGHOPE (NCT01416610)
- Where
- 10 sites in Austria
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
The purpose of this study is to see if it is safe and effective to give L-743,872 to patients with thrush, an AIDS-related yeast infection of the mouth, that has not been cured with fluconazole treatment.
- Trial name
- NCT00005920
- Testing
- L-743,872
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC